A target HbA1c of #7% may be considered. (Level of Evidence: C) 3. Less stringent HbA1c goals may be considered for patients with a history of severe hypoglycemia, limited life expectancy, advanced microvascular or macrovascular complications, or extensive comorbidities, or those in whom the goal is difficult to attain despite intensive therapeutic interventions. (Level of Evidence: C) Antiplatelet agents/anticoagulants Class I 1. Aspirin 75 162 mg daily is recommended in all patients with coronary artery disease unless contraindicated.64,81,82,116 (Level of Evidence: A) Clopidogrel 75 mg daily is recommended as an alternative for patients who are intolerant of or allergic to aspirin.117 (Level of Evidence: B) 2. A P2Y12 receptor antagonist in combination with aspirin is indicated in patients after ACS or PCI with stent placement.83 85 (Level of Evidence: A) For patients receiving a bare-metal stent or drug-eluting stent during PCI for ACS, clopidogrel 75 mg daily, prasugrel 10 mg daily, or ticagrelor 90 mg twice daily should be given for at least 12 months.84,86,113,114 (Level of Evidence: A) (Continued) Table 1. Continued Area for Intervention Recommendations Antiplatelet agents/anticoagulants cont d 3. For patients undergoing coronary artery bypass grafting, aspirin should be started within 6 hours after surgery to reduce saphenous vein graft closure. Dosing regimens ranging from 100 to 325 mg daily for 1 year appear to be efficacious.87 90 (Level of Evidence: A) 4. In patients with extracranial carotid or vertebral atherosclerosis who have had ischemic stroke or TIA, treatment with aspirin alone (75 325 mg daily), clopidogrel alone (75 mg daily), or the combination of aspirin plus extended-release dipyridamole (25 mg and 200 mg twice daily, respectively) should be started and continued.91,104,116 (Level of Evidence: B) 5. 